User contributions for Kosar Doraghi

13 February 2024

• 22:0022:00, 13 February 2024 diff hist +356‎ Vericiguat ‎No edit summary
• 21:5721:57, 13 February 2024 diff hist 0‎ N File:IMG 0813.jpeg ‎No edit summary current
• 21:5621:56, 13 February 2024 diff hist 0‎ N File:IMG 0812.jpeg ‎No edit summary current
• 21:5421:54, 13 February 2024 diff hist 0‎ N File:IMG 0817.jpeg ‎No edit summary current
• 21:5121:51, 13 February 2024 diff hist 0‎ N File:IMG 0818.jpeg ‎No edit summary current
• 21:5021:50, 13 February 2024 diff hist 0‎ N File:IMG 0816.jpeg ‎No edit summary current
• 21:4721:47, 13 February 2024 diff hist +11,303‎ N Vericiguat ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=VERQUVO-vericiguat |aOrAn=a |drugClass=soluble guanylate cyclase (sGC) stimulator |indicationType=treatment |indication=heart failure with reduced ejection fraction (HFrEF), reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less t..."
• 21:4321:43, 13 February 2024 diff hist 0‎ N File:IMG 0815.jpeg ‎No edit summary current
• 03:3003:30, 13 February 2024 diff hist +31‎ Tapinarof ‎No edit summary
• 03:2003:20, 13 February 2024 diff hist 0‎ N File:IMG 0810.jpeg ‎No edit summary current
• 03:1803:18, 13 February 2024 diff hist +5,123‎ N Tapinarof ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=VTAMA- tapinarof cream |aOrAn=an |drugClass=aryl hydrocarbon receptor agonist |indicationType=treatment |indication=plaque psoriasis in adults |adverseReactions=folliculitis, nasopharyngitis, contact dermatitis, headache, and pruritus |fdaLIADAdult=Cream, 1% Each gram of VTAMA cream contains 10 mg of tapinarof in a white to off-white cream. *Apply a thin layer of VTAMA cream to affected ar..."
• 03:1403:14, 13 February 2024 diff hist 0‎ N File:IMG 0809.jpeg ‎No edit summary current
• 03:1203:12, 13 February 2024 diff hist 0‎ N File:IMG 0808.jpeg ‎No edit summary current
• 03:1003:10, 13 February 2024 diff hist 0‎ N File:IMG 0807.jpeg ‎No edit summary current

12 February 2024

• 17:4017:40, 12 February 2024 diff hist +1,888‎ N Spevigo- spesolimab-sbz ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=spesolimab-sbzo |aOrAn=an |drugClass=interleukin-36 receptor antagonis |indicationType=treatment |indication=generalized pustular psoriasis flares in adults |hasBlackBoxWarning=Yes |adverseReactions=asthenia and fatigue, nausea and vomiting, headache, pruritus and prurigo, infusion site hematoma and bruising, and urinary tract infection. |blackBoxWarningTitle=Warning: Hyp..."

10 February 2024

• 06:1706:17, 10 February 2024 diff hist +22,457‎ N Ublituximab-xiiy ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=BRIUMVI™ (ublituximab-xiiy |aOrAn=a |drugClass=CD20-directed cytolytic antibody |indicationType=treatment |indication=relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults |hasBlackBoxWarning=Yes |adverseReactions=infusion reactions and upper respiratory..." current
• 06:1406:14, 10 February 2024 diff hist 0‎ N File:IMG 0806.jpeg ‎No edit summary current
• 06:1306:13, 10 February 2024 diff hist 0‎ N File:IMG 0805.jpeg ‎No edit summary current
• 06:0906:09, 10 February 2024 diff hist 0‎ N File:IMG 0799.jpeg ‎No edit summary current

7 February 2024

• 17:1517:15, 7 February 2024 diff hist +20,864‎ N LYTGOBI- futibatinib ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Futibatinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. This indication is approved under accelerated approval based on overall respons..." current
• 05:0305:03, 7 February 2024 diff hist 0‎ N File:IMG 0790.jpeg ‎No edit summary current
• 05:0105:01, 7 February 2024 diff hist 0‎ N File:IMG 0787.jpeg ‎No edit summary current
• 04:5604:56, 7 February 2024 diff hist 0‎ N File:IMG 0788.jpeg ‎No edit summary current

6 February 2024

• 22:3122:31, 6 February 2024 diff hist +418‎ Deucravacitinib ‎No edit summary current
• 22:1722:17, 6 February 2024 diff hist 0‎ N File:IMG 0786.jpeg ‎No edit summary current
• 22:0722:07, 6 February 2024 diff hist 0‎ N File:IMG 0785.jpeg ‎No edit summary current
• 22:0522:05, 6 February 2024 diff hist 0‎ N File:IMG 0782.jpeg ‎No edit summary current
• 21:4521:45, 6 February 2024 diff hist 0‎ N File:IMG 0783.jpeg ‎No edit summary current
• 21:4421:44, 6 February 2024 diff hist 0‎ N File:IMG 0784.jpeg ‎No edit summary current
• 21:1821:18, 6 February 2024 diff hist +25,798‎ N Deucravacitinib ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Deucravacitinib (SOTYKTU) |aOrAn=a |drugClass=tyrosine kinase 2 (TYK2) inhibitor |indicationType=treatment |indication=treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy |hasBlackBoxWarning=Yes |adverseReactions=hypersensitivity reaction, upper respiratory infections, blood creatine phosphokinase increased,..."

5 February 2024

• 23:3423:34, 5 February 2024 diff hist +2‎ RELYVRIO ‎No edit summary current
• 06:3706:37, 5 February 2024 diff hist +1‎ RELYVRIO ‎No edit summary
• 06:3406:34, 5 February 2024 diff hist −8‎ RELYVRIO ‎No edit summary
• 06:3206:32, 5 February 2024 diff hist +56‎ RELYVRIO ‎No edit summary
• 06:2506:25, 5 February 2024 diff hist +189‎ RELYVRIO ‎No edit summary
• 06:0006:00, 5 February 2024 diff hist 0‎ N File:IMG 0781.jpeg ‎No edit summary current
• 05:5205:52, 5 February 2024 diff hist −23‎ RELYVRIO ‎No edit summary
• 05:4905:49, 5 February 2024 diff hist +14,763‎ N RELYVRIO ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=sodium phenylbutyrate/taurursodiol |aOrAn=a |drugClass=drug that containing the active ingredients sodium phenylbutyrate and taurursodiol |indicationType=treatment |indication=amyotrophic lateral sclerosis (ALS) in adults. |hasBlackBoxWarning=Yes |adverseReactions=diarrhea, abdominal discomfort , nausea, and upper respiratory tract infection |blackBo..."
• 05:0505:05, 5 February 2024 diff hist 0‎ N File:IMG 0779.jpeg ‎No edit summary current
• 05:0405:04, 5 February 2024 diff hist 0‎ N File:IMG 0780.jpeg ‎No edit summary current

4 February 2024

• 23:1123:11, 4 February 2024 diff hist 0‎ N File:IMG 0777-sodium phenylbutyrate.jpeg ‎No edit summary current

2 February 2024

• 21:4021:40, 2 February 2024 diff hist +12‎ NEXOBRID ‎No edit summary current
• 21:3421:34, 2 February 2024 diff hist +56‎ NEXOBRID ‎No edit summary
• 21:0821:08, 2 February 2024 diff hist +84‎ NEXOBRID ‎No edit summary
• 20:5620:56, 2 February 2024 diff hist 0‎ N File:Nexobrid-02.jpg ‎No edit summary current
• 20:4420:44, 2 February 2024 diff hist 0‎ N File:Nexobrid-01.jpg ‎No edit summary current
• 04:1704:17, 2 February 2024 diff hist +29‎ NEXOBRID ‎No edit summary Tag: Visual edit: Switched
• 03:5103:51, 2 February 2024 diff hist +19,139‎ N NEXOBRID ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. |genericName=anacaulase-bcdb |aOrAn=a |indicationType=treatment |indication=eschar in adults with deep partial thickness or full thickness thermal burns. The safety and effectiveness of NEXOBRID have not been established for treatment of: Chemical or electrical burns, burns on the face, perineum, or genitalia, burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular..."

30 January 2024

• 22:3222:32, 30 January 2024 diff hist +98‎ Cholesteatoma ‎ →‎Overview current Tag: Visual edit

18 January 2024

• 21:0721:07, 18 January 2024 diff hist +70‎ N Template:KDRG ‎ Created page with "Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com]"